| Towards personalized treatment for early stage HER2-positive breast cancer K Goutsouliak, J Veeraraghavan, V Sethunath, C De Angelis, CK Osborne, ... Nature Reviews Clinical Oncology 17 (4), 233-250, 2020 | 261 | 2020 |
| FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer X Fu, R Pereira, C De Angelis, J Veeraraghavan, S Nanda, L Qin, ... Proceedings of the National Academy of Sciences 116 (52), 26823-26834, 2019 | 138 | 2019 |
| HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer X Xu, C De Angelis, KA Burke, A Nardone, H Hu, L Qin, J Veeraraghavan, ... Clinical Cancer Research 23 (17), 5123-5134, 2017 | 115 | 2017 |
| Activation of the IFN signaling pathway is associated with resistance to CDK4/6 inhibitors and immune checkpoint activation in ER-positive breast cancer C De Angelis, X Fu, ML Cataldo, A Nardone, R Pereira, J Veeraraghavan, ... Clinical Cancer Research 27 (17), 4870-4882, 2021 | 72 | 2021 |
| Integrative clinical and molecular characterization of translocation renal cell carcinoma Z Bakouny, A Sadagopan, P Ravi, NY Metaferia, J Li, S AbuHammad, ... Cell reports 38 (1), 2022 | 70 | 2022 |
| Targeting the mevalonate pathway to overcome acquired anti-HER2 treatment resistance in breast cancer V Sethunath, H Hu, C De Angelis, J Veeraraghavan, L Qin, N Wang, ... Molecular Cancer Research 17 (11), 2318-2330, 2019 | 57 | 2019 |
| Notch pathway activation is essential for maintenance of stem-like cells in early tongue cancer P Upadhyay, S Nair, E Kaur, J Aich, P Dani, V Sethunath, N Gardi, ... Oncotarget 7 (31), 50437, 2016 | 47 | 2016 |
| Evaluation of the predictive role of tumor immune infiltrate in patients with HER2-positive breast cancer treated with neoadjuvant anti-HER2 therapy without chemotherapy C De Angelis, C Nagi, CC Hoyt, L Liu, K Roman, C Wang, Y Zheng, ... Clinical Cancer Research 26 (3), 738-745, 2020 | 46 | 2020 |
| Drug-sensitiveFGFR3 mutations in lung adenocarcinoma P Chandrani, K Prabhash, R Prasad, V Sethunath, M Ranjan, P Iyer, ... Annals of oncology 28 (3), 597-603, 2017 | 46 | 2017 |
| A genome-scale CRISPR screen reveals PRMT1 as a critical regulator of androgen receptor signaling in prostate cancer S Tang, V Sethunath, NY Metaferia, MF Nogueira, DS Gallant, ER Garner, ... Cell reports 38 (8), 2022 | 29 | 2022 |
| GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer RR Bhat, P Yadav, D Sahay, DK Bhargava, CJ Creighton, S Yazdanfard, ... Breast cancer research and treatment 170, 279-292, 2018 | 24 | 2018 |
| HER2 L755S mutation is associated with acquired resistance to lapatinib and neratinib, and confers cross-resistance to tucatinib in HER2-positive breast cancer models J Veeraraghavan, R Mistry, S Nanda, V Sethunath, M Shea, T Mitchell, ... Cancer Research 80 (16_Supplement), 1911-1911, 2020 | 10 | 2020 |
| Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models J Veeraraghavan, C Gutierrez, V Sethunath, S Mehravaran, M Giuliano, ... NPJ Breast Cancer 7 (1), 63, 2021 | 7 | 2021 |
| Abstract GS2-01: High levels of interferon-response gene signatures are associated with de novo and acquired resistance to CDK4/6 inhibitors in ER+ breast cancer C De Angelis, X Fu, ML Cataldo, A Nardone, VM Jansen, ... Cancer Research 80 (4_Supplement), GS2-01-GS2-01, 2020 | 6 | 2020 |
| High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer X Fu, R Pereira, CC Liu, C De Angelis, MJ Shea, S Nanda, L Qin, ... Cell Reports 42 (8), 2023 | 3 | 2023 |
| Abstract PD3-09: HER2 L755S mutation is acquired upon resistance to lapatinib and neratinib and confers cross-resistance to tucatinib and trastuzumab in HER2 … J Veeraraghavan, R Mistry, S Nanda, V Sethunath, M Shea, T Mitchell, ... Cancer Research 81 (4_Supplement), PD3-09-PD3-09, 2021 | 3 | 2021 |
| Acquired neratinib resistance is associated with acquisition of HER2 and PIK3CA mutations and can be overcome using potent drug combinations in HER2 … J Veeraraghavan, R Mistry, S Nanda, S Bose, CC Liu, V Sethunath, ... Cancer Research 81 (13_Supplement), 1077-1077, 2021 | 1 | 2021 |
| High levels of interferon-response gene signatures are associated with de novo and acquired resistance to CDK4/6 inhibitors in ER plus breast cancer C De Angelis, X Fu, ML Cataldo, A Nardone, VM Jansen, ... CANCER RESEARCH 80 (4), 2020 | 1 | 2020 |
| Pro-oncogenic role of NOTCH1 in early tongue squamous cell carcinoma P Upadhyay, J Aich, V Sethunath, P Dani, S Kannan, P Chandrani, ... Cancer Research 75 (15_Supplement), 4811-4811, 2015 | 1 | 2015 |
| Effect of mevalonate pathway inhibitors on outcomes of patients (pts) with HER2-positive early breast cancer (BC) in the ALTTO trial. C De Angelis, J Veeraraghavan, V Sethunath, L Ameye, M Paesmans, ... Journal of Clinical Oncology 40 (16_suppl), 522-522, 2022 | | 2022 |
Amit DuttProfessor, Department of Genetics, University of Delhi South Campus, New Delhi--110029在 south.du.ac.in 的电子邮件经过验证
